The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I am still a strong advocate of fab and I believe it will do amazing. I stopped promoting it simply because my time in this game suggested to me that they needed a little extra cash after lack of news contracts and money in bank minus burn rate was released by company.
I only ever promote strong opportunities and I never talk others into buying when I think they could have bought cheaper. Some people love my honesty some hate it, but this isn’t a marriage of investor and company. We are here to make money.
I find the implications that I should continue to promote a company when the situation changes a bit off. I want to make money, I am good at this and I only ever talk about shares that I am buying at the time I buying.
For what it is worth the sp went up quite a bit several times since I mentioned it.
The start of a move by the looks, bottomed and up
Seems a bit harsh all u said was it looked weak.
Looks a little weak atm.
Amazed how many people can’t see the value in the current price. This is not a keep the lights on moment, this was clever and backed by strength.
I firmly believe we will see a bag or two in the coming months
Currently.
Time to buy in, average down, or take advantage. This is going to be worth more very soon.
See you when price is higher
I also started buying back in and will continue to do so
On sells, maybe an order being worked
I saw 250 a month too, but I can’t workout how it is so high, the cash from same broker not was 487k remaining end of sept which would imply they have run out of cash . However there was a comment in interview that’they were close to neural cash in cash out for at least one month.
So I guess it depends if the revenues in are continuing at that level or not.
there has been a real confusion over what is real and what is not. As the information in public domain is. Vague. If cash in is continuing to cover costs then obviously no need for. A cash injection, but it is a slightly risky operating model to be on the bread line, so to speak.
so do they try and continue with hope that bigger contracts will land and potential grant kicks in. Or do they take an injection of cash and have a much bigger safety net.
Who knows
Today
Https://x.com/dds_docholiday/status/1734563149100015826?s=61
Through 1 this time
We are going up
Easy bagger from down here
Wow that is one of the most positive and bullish interviews I have heard for a long long time. To have a CEO sound so happy and use words like buzzing, absolutely delighted, best we could have hoped, major news, looking forward and good for mankind and animal kind.
Well done Adrian and congratulations on the start of what I believe will be a #fab future.
Morning all hopefully a nice bounce roday
:-)
Be nice to go red to blue
Reflecting on our recent announcement, our CEO Adrian Kinkaid has made the following comments:
"I am delighted to have the agreement to work with NCI, one of the best possible partners at this stage of development.
Three of the key benefits of OptiMAL® in the discovery of novel antibodies are highly significant. The platform enables screening with:
1. fully intact IgG antibodies (rather than fragments which have to be stitched together often to the detriment of binding efficacy)
2. antibodies expressed in a mammalian cell (the preferred system for production of therapeutic antibodies)
3. a highly diverse library of sequences based on Fusion's proprietary design methods using the human immune repertoire
All of these are entirely consistent with the Fusion philosophy to 'begin with the end in mind'.
Any one wanting further information on this ground breaking antibody discovery platform should contact Fusion: info@fusionantibodies.com , or myself."